HERON THERAPEUTICS, INC. /DE/ (HRTX) Net margin 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) net profit margin by fiscal year — reported net income divided by reported revenue.
-13.0%FY2025 · since FY2016: -13537.4% → -13.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -13.0% | -3.6 pp |
| FY2024 | -9.4% | +77.6 pp |
| FY2023 | -87.0% | +82.0 pp |
| FY2022 | -169.1% | +86.5 pp |
| FY2021 | -255.6% | +0.8 pp |
| FY2020 | -256.4% | -116.1 pp |
| FY2019 | -140.3% | +90.6 pp |
| FY2018 | -230.8% | +411.0 pp |
| FY2017 | -641.9% | +12895.5 pp |
| FY2016 | -13537.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Gross profitHRTX Gross marginHRTX Operating incomeHRTX Operating marginHRTX Operating cash flowHRTX Free cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →